Multiple non-statin therapies effectively control cholesterol levels and could be prescribed as mono- or combined therapy in FH patients, including ezetimibe, PCSK9 inhibitors, mipomersen, and lomitapide. Here, PCSK9 is linked to familial hyperaldosteronism.